Aknar Calabrich
Research Subjects
Research Interests
Aknar Calabrich has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Clarissa Baldotto
Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro
3 shared publications - Carlos Gil Ferreira
Grupo Oncoclinicas
2 shared publications - Danielli Matias
Liga Norte Riograndense Contra O Câncer, Natal, Brazil
2 shared publications - Eduardo Cronemberger
Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Brazil
2 shared publications - Tatiane Montella
Núcleo de Excelência em Oncologia Torácica, Rio de Janeiro, Brazil
2 shared publications - Adriana Batista Alves
Clínica AMO, Salvador, BA, Brasil
1 shared publication
Latest Publications
- 24 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Real-world disparities in molecular diagnosis of diffuse gliomas in Brazil: Insights from LACOG 0619
Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.
- 24 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Real-world disparities in molecular diagnosis of diffuse gliomas in Brazil: Insights from LACOG 0619
Background: Diffuse gliomas in adults are rare, aggressive central nervous system (CNS) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods: This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from 9 centers in Brazil (2010-2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results: A total of 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and Next-Generation Sequencing testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with 5-year overall survival ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (P < .001), confirming the prognostic impact of molecular testing. Conclusions: LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- 22 July 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (4) , 882-895
Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors
Introduction: Precision medicine has revolutionized oncology, providing more personalized diagnosis, treatment, and monitoring for patients with cancer. In the context of female‐specific tumors, such as breast, ovarian, endometrial, and cervical cancer, proper tissue collection and handling are essential for obtaining tissue, immunohistochemical (IHC), and molecular data to guide therapeutic decisions.Objectives: To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.Method: The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.Conclusion: The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.
- 22 July 2024
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (4) , 882-895
Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors
Introduction: Precision medicine has revolutionized oncology, providing more personalized diagnosis, treatment, and monitoring for patients with cancer. In the context of female‐specific tumors, such as breast, ovarian, endometrial, and cervical cancer, proper tissue collection and handling are essential for obtaining tissue, immunohistochemical (IHC), and molecular data to guide therapeutic decisions.Objectives: To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.Method: The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.Conclusion: The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.
- Open Access
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (9) , e2200426
EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
PURPOSE: There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS: This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS: A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION: This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (9) , e2200426
Open AccessEGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
PURPOSE: There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim of this study was to retrospectively analyze epidermal growth factor receptor (EGFR) mutations detected in a real-world scenario using a large cohort of Brazilian patients with non–small-cell lung cancer (NSCLC). MATERIALS AND METHODS: This was a cross-sectional, observational, descriptive study on the basis of a database of EGFR molecular analysis from tumor samples of patients with a confirmatory histopathological diagnosis of primary lung cancer. Specimens were collected from 2013 to 2017 and were tested using cobas, next-generation sequencing, and Sanger sequencing platforms. RESULTS: A total of 7,413 tumor specimens were tested. The patients were predominantly women with a median age of 67.0 years. Patients with at least one mutation represented 24.2% of the total sample. Among the positive patients, the majority had just one mutation, but two or more simultaneous mutations were observed in 1.52% of patients. Exon 19 deletion was the most prevalent alteration in the sample (12.8%), followed by exon 21 L858R (6.9%) and exon 20 insertion (1.6%). All others were considered uncommon mutations and were observed in 18.5% of all mutated patients and 4.0% of the total sample (2.3%-18.7% depending on the sequencing method). CONCLUSION: This study examined the prevalence of EGFR mutations in Brazilian patients with NSCLC using different technologies, suggesting that the type of method used, directed or nondirected against specific mutations, influences the analysis, particularly for uncommon mutations, which will be missed by mutation-specific approaches such as cobas testing. Our estimates are the largest in Latin America and are consistent with previous reports from other parts of the world. Besides the variability in methods described here as technology incorporation advances in a nonhomogeneous manner, it is probably like the real-world clinical setting Brazilian oncologists face in their daily practice.
- Open Access
- 1 January 2023
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 19 (CP) , 1-9
PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil
To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March 2021 and comprised 20 medical oncologists focus on gynecological oncology. The panel answered anonymously and based on scientific evidence a total of 67 questions. The panel reached consensus (at least 75% of votes for the same recommendation) or majority vote (50% to 74.9%) for the majority of questions that addressed: (1) who and when to test for BRCA mutations or homologous recombination deficiency (2) what test should be used; (3) when should maintenance PARP inhibitor therapy be indicated; (4) which PARP inhibitor should be used; (5) when should bevacizumab be combined; and (6) toxicity management. The current recommendations may help Brazilian practitioners to improve the use of PARP inhibitors in front-line management of EOC.
- 1 January 2023
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 19 (CP) , 1-9
Open AccessPARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil
To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March 2021 and comprised 20 medical oncologists focus on gynecological oncology. The panel answered anonymously and based on scientific evidence a total of 67 questions. The panel reached consensus (at least 75% of votes for the same recommendation) or majority vote (50% to 74.9%) for the majority of questions that addressed: (1) who and when to test for BRCA mutations or homologous recombination deficiency (2) what test should be used; (3) when should maintenance PARP inhibitor therapy be indicated; (4) which PARP inhibitor should be used; (5) when should bevacizumab be combined; and (6) toxicity management. The current recommendations may help Brazilian practitioners to improve the use of PARP inhibitors in front-line management of EOC.
- Open Access
- 1 March 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (3) , 338-344
Oncology practice during COVID-19 pandemic: a fast response is the best response
SUMMARY The first confirmed case of coronavirus disease 2019 (COVID-19) in Brasil was reported on February 25th, 2020, and by April 3rd, 8076 were confirmed in the country. As COVID-19 disease incidence escalates in Brasil, management of cancer patients requires immediate action and oncology clinics are urged to establish a contingency plan. We have installed a COVID-19 Management Committee to elaborate and implement best practices to assist cancer outpatients as well as to provide a safe environment for clinical staff and other employees at the outpatient clinics. The challenges of cancer treatment in the midst of COVID-19 global pandemic highlight the importance of a rapid response by institutions, where organizational structure, strategic planning, agility in guidelines implementation and alternative ways to protect and support clinical staff, employees and patients may be the key to mitigate pandemic effects.
- 1 March 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (3) , 338-344
Open AccessOncology practice during COVID-19 pandemic: a fast response is the best response
SUMMARY The first confirmed case of coronavirus disease 2019 (COVID-19) in Brasil was reported on February 25th, 2020, and by April 3rd, 8076 were confirmed in the country. As COVID-19 disease incidence escalates in Brasil, management of cancer patients requires immediate action and oncology clinics are urged to establish a contingency plan. We have installed a COVID-19 Management Committee to elaborate and implement best practices to assist cancer outpatients as well as to provide a safe environment for clinical staff and other employees at the outpatient clinics. The challenges of cancer treatment in the midst of COVID-19 global pandemic highlight the importance of a rapid response by institutions, where organizational structure, strategic planning, agility in guidelines implementation and alternative ways to protect and support clinical staff, employees and patients may be the key to mitigate pandemic effects.
- Open Access
Reversible Serum Carcinoembriogenic Antigen (CEA) Elevation Due to Orlistat Use: A Case Report